title: [Study on a 10-year protective effects of vaccination against hemorrhagic fever with renal syndrome].
abstract: OBJECTIVE
  To evaluate the epidemiological and serological efficacy after 10 years of vaccination against hemorrhagic fever with renal syndrome (HFRS) vaccines in Zhejiang province.
  
  
  METHODS
  One county was randomly chosen as the research unit with all the healthy people between 16 and 60 years old were equally divided into study and control groups. The study group was vaccinated. Immunofluorescent antibody assay was used to test specific IgG antibody and Mcro-CPE method was used to test the titer of neutralizing antibody.
  
  
  RESULTS
  Two weeks after the full-course immunization, the seroconversion rate became 100% (67/67, with 95% CI as 96.3%-100%) by immunofluorescent antibody test (IgG) and 44.4% (8/18 with 95% CI as 22.0%-69.0%) by neutralization test with GMT titers as 72.1 and 4.6 respectively. Booster immunization was provided one year later. Time span as two weeks prior to, one year, one and half years, two years, three years and five years after booster immunization, the rates of seroconversion on immunofluorescent antibody using IFAT method, were 28.6%, 83.3%, 75.0%, 53.1%, 22.6%, 10.0% and 55.0% respectively, and rates of seroconversion of neutralizing antibody by Mcro-CPE method were 14.8%, 55.6%, 35.0%, 31.3%, 26.0%, 10.0% and 50.0% respectively. Nine years after the reinforcement, the rates of seroconversion of immunofluorescent antibody by IFAT method was only 7.1%. The vaccinated group had no patient seen but the control group appeared 34 patients including 3 deaths. According to the ten-year observation, the vaccine seemed effective with the protection rate in population reached 100%.
  
  
  CONCLUSIONS
  HFRS vaccine was effective on epidemiological, social and economical efficacy.
authors.affiliation: Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310009, China.
authors.forename: Zhen-Yu
authors.initials: ZY
authors.lastname: Gong
authors.forename: Jing-Qing
authors.initials: JQ
authors.lastname: Weng
authors.forename: Jin-Bao
authors.initials: JB
authors.lastname: Lei
authors.forename: Chun-Fu
authors.initials: CF
authors.lastname: Fang
authors.forename: En-Fu
authors.initials: EF
authors.lastname: Chen
authors.forename: Zhen
authors.initials: Z
authors.lastname: Wang
authors.forename: Zhong-Bing
authors.initials: ZB
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Fan
authors.initials: F
authors.lastname: He
authors.forename: Bi-Yao
authors.initials: BY
authors.lastname: Liu
authors.forename: Jun-Fen
authors.initials: JF
authors.lastname: Lin
authors.forename: Gang-Qiang
authors.initials: GQ
authors.lastname: Ding
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods; D008297:Male; D008875:Middle Aged; D051381:Rats; D014611:Vaccination / Q000379:methods*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D014765:Viral Vaccines